◀ Back to ABL1

ABL1 — LYN

Text-mined interactions from Literome

Fiskus et al., Clin Cancer Res 2006 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Treatment with dasatinib attenuated the levels of autophosphorylated Bcr-Abl , p-CrkL, phospho-signal transducer and activator of transcription 5 ( p-STAT5 ), p-c-Src, and p-Lyn ; inhibited the activity of Lyn and c-Src ; and induced apoptosis of the cultured CML cells
Wu et al., Blood 2008 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
Yu et al., Carcinogenesis 2008 (Cell Transformation, Neoplastic...) : Abi1 contributes to Bcr-Abl induced leukemogenesis in part through Src family kinases, as the knock down of Abi1 expression attenuates Bcr-Abl stimulated activation of Lyn
Wu et al., J Natl Cancer Inst 2008 (Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative) : LYN activation was independent of BCR-ABL in cells from imatinib-resistant patients
Mahon et al., Cancer Res 2008 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn , and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn
Tabe et al., Leukemia 2012 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Src related kinase Lyn is known to interact with CXCL12/CXCR4 signaling and is directly activated by p210 Bcr-Abl